Empowered Funds LLC Increases Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Empowered Funds LLC boosted its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 5.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,767 shares of the company’s stock after acquiring an additional 3,350 shares during the quarter. Empowered Funds LLC owned about 0.18% of iTeos Therapeutics worth $671,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ITOS. Clearline Capital LP purchased a new position in shares of iTeos Therapeutics in the second quarter valued at $2,328,000. Candriam S.C.A. purchased a new position in iTeos Therapeutics in the 2nd quarter valued at about $7,558,000. Kennedy Capital Management LLC acquired a new stake in shares of iTeos Therapeutics during the first quarter valued at about $1,988,000. Dimensional Fund Advisors LP increased its position in shares of iTeos Therapeutics by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after acquiring an additional 117,159 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of iTeos Therapeutics by 26.5% in the second quarter. American Century Companies Inc. now owns 46,322 shares of the company’s stock worth $687,000 after acquiring an additional 9,717 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

Insider Activity

In related news, CFO Matthew Gall purchased 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average price of $7.73 per share, with a total value of $38,650.00. Following the acquisition, the chief financial officer now owns 65,429 shares in the company, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 12.50% of the company’s stock.

iTeos Therapeutics Trading Up 2.3 %

Shares of NASDAQ ITOS opened at $8.32 on Friday. The company has a market capitalization of $303.93 million, a price-to-earnings ratio of -2.64 and a beta of 1.39. iTeos Therapeutics, Inc. has a twelve month low of $7.54 and a twelve month high of $18.75. The business has a 50 day simple moving average of $9.45 and a 200-day simple moving average of $13.86.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. As a group, equities analysts predict that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current year.

Analysts Set New Price Targets

ITOS has been the subject of a number of recent analyst reports. Wells Fargo & Company started coverage on iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a research note on Friday, November 15th. Wedbush reiterated an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research report on Monday, August 12th.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.